


## Attention-Deficit/Hyperactivity Disorder (ADHD)

The review examined the efficacy and safety of treatments for ADHD in 8 meta-analyses and 28 clinical trials, assessing 39,310 patients including both children and adults. The findings showed that generic options are high value and similarly effective to higher cost options like Azstarys for the management of ADHD in both children and adults.

### Comparative Effectiveness: Key Findings


#### For Children (12 and under):

- Generic Focalin XR, generic Concerta, generic Ritalin, generic Vyvanse, and Jornay PM were similarly effective for change in the parent rating scale and met the Minimum Clinically Important Difference (MCID) for this outcome.
- In children less than 12, Azstarys did not meet the MCID but was statistically better than placebo for this age group.
  - Azstarys was FDA approved in children over the age of 12 based on bioequivalence to generic Focalin XR.



#### For Adults:

- Generic Concerta, generic Ritalin LA, generic Adderall, and Vyvanse were similarly effective for change in the ADHD Self-Report Scale.
- Azstarys was FDA approved in adults based on bioequivalence to generic Focalin XR.



**TruCard Coverage Tier**

Bubble size represents relative utilization. Outlined bubble represents no utilization.

- Tier 1
- Tier 2
- Non-Formulary

**2026 Formulary Coverage & Member Cost**

	Drug Name	Coverage Tier & Member Copay	Key Status
<b>Long Acting Agents</b>	generic Adderall XR generic Concerta generic Focalin XR generic Metadate CD generic Dexedrine	Tier 1: \$60/Year	High-Value Options (highly effective, lower cost)
	lisdexamfetamine (generic Vyvanse)	Tier 1: \$60/Year PA required <i>(for new utilizers only)</i>	Requires trial of high value options
	Vyvanse (brand) Jornay PM Azstarys	Non-Formulary: \$360/Year	Lower-value therapies; requires trial of preferred formulary options
<b>Short Acting Agents</b>	generic Adderall generic Ritalin generic Focalin generic Methylin ER	Tier 1: \$60/Year	High-Value Options (highly effective, lower cost)

	Drug Name	Coverage Tier & Member Copay	Key Status
	generic Evekeo generic Zenzedi generic Methylin solution Procentra solution		
	Evekeo Zenzedi Adderall Focalin	Non-Formulary: \$360/Year	Lower-value therapies; requires trial of preferred formulary options

### Prescribing Strategy & Transition Plan

**Initial Management (New Starts):** Initiate therapy with high-value generic options such as generic Concerta, generic Focalin XR, or generic Adderall XR.

**Managing Established Patients (Transition Plan):** Current utilizers of lisdexamfetamine, Jornay PM, and Azstarys will be provided with continuation of care, and no action is required, with the exception of patients on brand Vyvanse. Members on brand Vyvanse will need to transition to either lisdexamfetamine (generic Vyvanse) or another covered option (e.g. generic Concerta, generic Adderall XR, etc.) after 1/1/2026.

### Prior Authorization (PA) Criteria at a Glance

- **For lisdexamfetamine (generic Vyvanse):** The prior authorization criteria applies to new utilizers only and requires a documented trial and failure (at least 60 days), intolerance, or contraindication to both a long-acting methylphenidate product (e.g., generic Concerta) AND a long-acting amphetamine product (e.g., generic Adderall XR).
- **For Non-Formulary Requests:** Documented trial and failure (at least 60 days), intolerance, or contraindication to both a long-acting methylphenidate product (e.g., generic Concerta) AND a long-acting amphetamine product (e.g., generic Adderall XR); AND trial/failure, intolerance, or contraindication to lisdexamfetamine (PA required).